Literature DB >> 20814162

Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population.

Mi-Sun Hwang1, Su-Jun Lee, Hye-Eun Jeong, Sangseop Lee, Mi-Ae Yoo, Jae-Gook Shin.   

Abstract

Glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) has been identified as an important pathway for the elimination of its substrate drugs in humans. Alterations in UGT2B7 function or expression may influence individual variations in drug responses. In an effort to screen for UGT2B7 single nucleotide polymorphisms (SNPs) in Koreans, the UGT2B7 gene was directly sequenced in 50 normal subjects. A total of 19 genetic variations were found: seven in exons, eight in introns, and four in the 5'-untranslated region. The order of the frequency distribution of UGT2B7 variations was: -900A>G, -327G>A, -161C>T, 10539A>G, 10711G>C and 10806T>A (40%); 2099T>A, 2100C>T, 2283A>G and 2316A>G (39%); 12029T>A (37%); 10928C>A (33%); 10541G>A (28%); 10897insA (24%); 372A>G (13%) and 211G>T (12%), as well as other minor alleles with less than 10% frequency. Nineteen variations were used to characterize linkage disequilibrium (LD) structures at the UGT2B7 locus. Eight tagging SNPs in UGT2B7 were determined. Identification of UGT2B7 SNPs with LD and the tagging SNPs lays the foundation for investigating UGT2B7-related genotype/phenotype association studies for Koreans as well as other populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20814162     DOI: 10.2133/dmpk.dmpk-10-sc-021

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  8 in total

1.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

2.  The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.

Authors:  Zi-Zhao Yang; Li Li; Lu Wang; Ling-Min Yuan; Ming-Cheng Xu; Jing-Kai Gu; Hui-di Jiang; Lu-Shan Yu; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

3.  Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation.

Authors:  Yazun Bashir Jarrar; Eun-Young Cha; Kyung-Ah Seo; Jong-Lyul Ghim; Hyo-Ji Kim; Dong-Hyun Kim; Su-Jun Lee; Jae-Gook Shin
Journal:  J Lipid Res       Date:  2014-09-23       Impact factor: 5.922

4.  Charactering the metabolism of cryptotanshinone by human P450 enzymes and uridine diphosphate glucuronosyltransferases in vitro.

Authors:  Jin Zeng; Yu-Juan Fan; Bo Tan; Hui-Zong Su; Yue Li; Lin-Lin Zhang; Jian Jiang; Fu-Rong Qiu
Journal:  Acta Pharmacol Sin       Date:  2018-02-08       Impact factor: 6.150

5.  Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.

Authors:  Yinhua Li; Yuting Mu; Haihong Shi; Yali Liang; Zeyuan Liu; Kyle Matschke; Anne Hickman; Rajesh Krishna; Vaishali Sahasrabudhe
Journal:  Clin Pharmacol Drug Dev       Date:  2019-04-01

6.  Glucuronidation of [6]-shogaol, [8]-shogaol and [10]-shogaol by human tissues and expressed UGT enzymes: identification of UGT2B7 as the major contributor.

Authors:  Liangliang He; Jinjin Xu; Qi Wang; Yezi Zhang; Zifei Qin; Yang Yu; Zhengming Qian; Zhihong Yao; Xinsheng Yao
Journal:  RSC Adv       Date:  2018-12-12       Impact factor: 4.036

7.  Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations.

Authors:  Daryl J Fediuk; Vaishali Sahasrabudhe; Vikas Kumar Dawra; Susan Zhou; Kevin Sweeney
Journal:  Clin Pharmacol Drug Dev       Date:  2021-07-02

8.  Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.

Authors:  Yinhua Li; Gianluca Nucci; Yuichi Yamamoto; Daryl J Fediuk; Vaishali Sahasrabudhe
Journal:  Clin Pharmacol Drug Dev       Date:  2021-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.